Longitudinal Evaluation of the Novel Psoriatic Arthritis 5-Thermometer Scale (PsA-5Ts) Domains During Treatment with Guselkumab: Pooled Analysis of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies

被引：0
|
作者：
Selmi, Carlo [1 ]
Salaffi, Fausto [2 ]
Aydin, Sibel [3 ]
Soriano, Enrique [4 ,5 ]
Rampakakis, Emmanouil [6 ]
Sharaf, Mohamed [7 ]
Zimmermann, Miriam [8 ]
Lavie, Frederic [9 ]
Nash, Peter [10 ]
Mease, Philip J. [11 ,12 ]
机构：
[1] Humanitas Univ, Humanitas Res Hosp, Rheumatol & Clin Immunol, Internal Med, Rozzano, Italy
[2] Polytech Univ Marche, Carlo Urbani Hosp, Dept Clin & Mol Sci, Ancona, Italy
[3] Ottawa Hosp Riverside Campus, Dept Med, Ottawa, ON, Canada
[4] Hosp Italiano Buenos Aires, Internal Med Serv, Rheumatol Sect, Buenos Aires, DF, Argentina
[5] Univ Inst Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina
[6] McGill Univ, Dept Pediat, Sci Affairs, JSS Med Res, Montreal, PQ, Canada
[7] Janssen MEA, Immunol, Dubai, U Arab Emirates
[8] Janssen Med Affairs LLC, Immunol, Zug, Switzerland
[9] Johnson & Johnson, Janssen Pharmaceut Co, Paris, France
[10] Griffith Univ, Sch Med, Brisbane, Qld, Australia
[11] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA
[12] Univ Washington, Sch Med, Seattle, WA USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1429
引用
收藏
页码：2809 / 2811
页数：3
相关论文
共 50 条
  • [31] Long-term Efficacy of Guselkumab (GUS) on Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study in Biologic-na_ive Patients With Psoriatic Arthritis (PsA)
    Gladman, Dafna D.
    Starr, Michael
    Ranza, Roberto
    Bravo, Ana-Maria
    Strauss, Marcie
    Shawi, May
    Han, Chenglong
    Rampakakis, Emmanouil
    Ostor, Andrew
    Mease, Philip J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB189 - AB189
  • [32] Efficacy of Fremanezumab Treatment in Patients ≥60 Years of Age With Episodic or Chronic Migraine: Pooled Results of 3 Randomized, Double-Blind, Placebo-controlled Phase 3 Studies
    Nahas, S. J.
    Ning, X.
    Cohen, J. M.
    Yang, R.
    Ramirez-Campos, V
    Silberstein, S. D.
    HEADACHE, 2020, 60 : 14 - 15
  • [33] RISANKIZUMAB FOR ACTIVE PSORIATIC ARTHRITIS: INTEGRATED SUBGROUP ANALYSIS FROM 2 DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDIES (KEEPSAKE 1 AND KEEPSAKE 2)
    Merola, J. F.
    Callis-Duffin, K.
    Padilla, B.
    Xue, Z.
    Photowala, H.
    Kaplan, B.
    Mcinnes, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 829 - 830
  • [34] Sex-Related Differences in Baseline Patient and Disease Characteristics: Post Hoc Analyses of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies in Patients with Active Psoriatic Arthritis
    Coates, Laura
    Selmi, Carlo
    Mease, Philip
    Ogdie, Alexis
    Nantel, Francois
    Lavie, Frederic
    Sharaf, Mohamed
    Adelakun, Oyediran
    Rampakakis, Emmanouil
    Vegas, Laura Pina
    Eder, Lihi
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 1198 - 1200
  • [35] DESIGNING A PHASE 3B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF GUSELKUMAB DOSING INTERVAL IN PSORIATIC ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITION
    Ogdie, A.
    Merola, J. F.
    Mease, P. J.
    Ritchlin, C. T.
    Scher, J. U.
    Chan, D.
    Chakravarty, S. D.
    Langholff, W.
    Choi, O.
    Krol, Y.
    Rowland, K.
    Gottlieb, A. B.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1567 - 1568
  • [36] Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1)
    Kameda, Hideto
    Hagimori, Kohei
    Morisaki, Yoji
    Holzkaemper, Thorsten
    Konomi, Ayako
    Dobashi, Hiroaki
    RHEUMATOLOGY AND THERAPY, 2023, 10 (06) : 1683 - 1703
  • [37] Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1)
    Hideto Kameda
    Kohei Hagimori
    Yoji Morisaki
    Thorsten Holzkämper
    Ayako Konomi
    Hiroaki Dobashi
    Rheumatology and Therapy, 2023, 10 : 1683 - 1703
  • [38] GUSELKUMAB, AN ANTI-INTERLEUKIN-23P19 MONOCLONAL ANTIBODY, IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: WEEK 24 RESULTS OF THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Mease, Philip J.
    Rahman, Proton
    Gottlieb, Alice
    Hsia, Elizabeth
    Kollmeier, Alexa P.
    Xu, Xie L.
    Subramanian, Ramanand A.
    Agarwal, Prasheen
    Sheng, Shihong
    Zhou, Bei
    van der Helide, Desiree
    Zazzetti, Federico
    McInnes, Lin B.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 23 - 23
  • [39] Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naive Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study
    Mease, Philip J.
    Rahman, Proton
    Gottlieb, Alice B.
    Hsia, Elizabeth
    Kollmeier, Alexa
    Xu, Xie
    Subramanian, Ramanand
    Agarwal, Prasheen
    Sheng, Shihong
    Zhou, Bei
    van der Heijde, Desiree
    McInnes, Iain
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [40] Consistent and significant improvement of nighttime voiding frequency (nocturia) with silodosin in men with LUTS suggestive of BPH: pooled analysis of three randomized, placebo-controlled, double-blind phase III studies
    Andreas Eisenhardt
    Tim Schneider
    Francisco Cruz
    Matthias Oelke
    World Journal of Urology, 2014, 32 : 1119 - 1125
12345